JP2023553117A5 - - Google Patents

Info

Publication number
JP2023553117A5
JP2023553117A5 JP2023535012A JP2023535012A JP2023553117A5 JP 2023553117 A5 JP2023553117 A5 JP 2023553117A5 JP 2023535012 A JP2023535012 A JP 2023535012A JP 2023535012 A JP2023535012 A JP 2023535012A JP 2023553117 A5 JP2023553117 A5 JP 2023553117A5
Authority
JP
Japan
Prior art keywords
optionally
infection
treatment
recombinant protein
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023535012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553117A (ja
JP7857940B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062168 external-priority patent/WO2022125523A1/en
Publication of JP2023553117A publication Critical patent/JP2023553117A/ja
Publication of JP2023553117A5 publication Critical patent/JP2023553117A5/ja
Application granted granted Critical
Publication of JP7857940B2 publication Critical patent/JP7857940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023535012A 2020-12-08 2021-12-07 顆粒球マクロファージコロニー刺激因子の製造 Active JP7857940B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063122593P 2020-12-08 2020-12-08
US63/122,593 2020-12-08
US202163271444P 2021-10-25 2021-10-25
US63/271,444 2021-10-25
PCT/US2021/062168 WO2022125523A1 (en) 2020-12-08 2021-12-07 Manufacture of granulocyte macrophage-colony stimulating factor

Publications (3)

Publication Number Publication Date
JP2023553117A JP2023553117A (ja) 2023-12-20
JP2023553117A5 true JP2023553117A5 (enExample) 2024-12-17
JP7857940B2 JP7857940B2 (ja) 2026-05-13

Family

ID=81974806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535012A Active JP7857940B2 (ja) 2020-12-08 2021-12-07 顆粒球マクロファージコロニー刺激因子の製造

Country Status (5)

Country Link
US (1) US20240043486A1 (enExample)
EP (1) EP4259774A4 (enExample)
JP (1) JP7857940B2 (enExample)
CA (1) CA3201327A1 (enExample)
WO (1) WO2022125523A1 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
EP1318834A2 (en) * 2000-09-12 2003-06-18 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
WO2006019950A2 (en) * 2004-07-16 2006-02-23 Nektar Therapeutics Al, Corporation Conjugates of a gm-csf moiety and a polymer
CN101512001A (zh) 2006-07-14 2009-08-19 诺维信股份有限公司 提高真菌细胞中基因表达的方法
CA2903589A1 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Cell culture media and methods of antibody production
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
CA2942770A1 (en) * 2014-03-23 2015-10-01 Advantech Bioscience Farmaceutica Ltda. Enhancement of recombinant protein expression with copper

Similar Documents

Publication Publication Date Title
Zhang et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Akbari et al. Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia
Ghaffari et al. Eosinophils in the tumor microenvironment: implications for cancer immunotherapy
Liu et al. Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome
US20230084300A1 (en) Prevention and treatment of infections including those caused by coronavirus
Cancio et al. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies
US20220218817A1 (en) Immune modulation by mesenchymal stem cells
Rao et al. Mesenchymal stem cells-bridge catalyst between innate and adaptive immunity in COVID 19
Sanchez et al. Expression of inducible CC chemokines in rainbow trout (Oncorhynchus mykiss) in response to a viral haemorrhagic septicemia virus (VHSV) DNA vaccine and interleukin 8
JP2024524485A (ja) 造血幹・前駆細胞からの形質細胞様樹状細胞のｃｇｍｐに準拠した作製及び増殖
CA3211351A1 (en) Populations of enriched regulatory t cells and methods for producing same
CA3211348A1 (en) Compositions comprising regulatory t cells and methods of using the same
JP2025501746A5 (enExample)
Zhang et al. Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy
US20230181637A1 (en) Nk cells and uses thereof for treatment of microbial infections
Widowati et al. Allogeneic mesenchymal stem cells and its conditioned medium as a potential adjuvant therapy for COVID-19
Maurya et al. Novel stem cells and nucleic acid-based vaccine trials against viral outbreak: a systematic evaluation during COVID-2019 pandemic
Lam et al. Targeting mesenchymal stem cell therapy for severe pneumonia patients
Malkan et al. Hematological aspects of the COVID-19 syndrome.
JP2023521671A (ja) Ｃｏｖｉｄ－１９感染症に対する幹細胞免疫調節療法
Krivoshlykova et al. Serum concentrations of pro-and anti-inflammatory cytokines in Wistar rats subjected to immobilization stress and treated with Tuftsin-pro-Gly-pro peptide
JP2023547883A5 (enExample)
US20230127499A1 (en) Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus
WO2022056092A1 (en) Methods of treating viral infection
US20220233643A1 (en) TARGETING LUNG-RESIDENT TNFR2+ cDC2 (R2D2) SUBPOPULATION TO TREAT ASTHMA